Literature DB >> 17802917

Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management.

Isabella Bon1, Federica Alessandrini, Marco Borderi, Roberta Gorini, Maria Carla Re.   

Abstract

Genotypic resistance analysis on viral DNA and plasma was performed in 56 therapy naive patients with recent and chronic infection to assess the prevalence of mutations associated with drug resistance and compare cell-free and cell-associated strains. Direct sequencing of DNA provirus disclosed key mutations to RT inhibitors more frequently than in plasma RNA. In addition, major mutations associated with drug resistance in the PR region were only found in PBMCs. Although our data are limited to a small cohort, they show a different resistance profile between plasma and PBMC compartments and may yield additional information for first-line antiretroviral regimens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17802917

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  8 in total

1.  Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1.

Authors:  Lauren Banks; Sharareh Gholamin; Elizabeth White; Lynn Zijenah; David A Katzenstein
Journal:  J AIDS Clin Res       Date:  2012-02

2.  Enhanced detection of viral diversity using partial and near full-length genomes of human immunodeficiency virus Type 1 provirus deep sequencing data from recently infected donors at four blood centers in Brazil.

Authors:  Rodrigo Pessôa; Jaqueline Tomoko Watanabe; Paula Calabria; Cecilia Salete Alencar; Paula Loureiro; Maria Esther Lopes; Anna Barbara Proetti; Alvina Clara Félix; Ester C Sabino; Michael P Busch; Sabri S Sanabani
Journal:  Transfusion       Date:  2014-11-21       Impact factor: 3.157

3.  Comparison of HIV-1 resistance profiles in plasma RNA versus PBMC DNA in heavily treated patients in Honduras, a resource-limited country.

Authors:  Karidia Diallo; Wendy E Murillo; Ivette Lorenzana de Rivera; Jan Albert; Zhiyong Zhou; John Nkengasong; Guoqing Zhang; Jennifer F Sabatier; Chunfu Yang
Journal:  Int J Mol Epidemiol Genet       Date:  2012-02-28

4.  HIV drug resistance mutations in proviral DNA from a community treatment program.

Authors:  Anne Derache; Hyoung-Shik Shin; Maya Balamane; Elizabeth White; Dennis Israelski; Jeffrey D Klausner; Alexandra H Freeman; David Katzenstein
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

5.  Deep sequencing of HIV-1 near full-length proviral genomes identifies high rates of BF1 recombinants including two novel circulating recombinant forms (CRF) 70_BF1 and a disseminating 71_BF1 among blood donors in Pernambuco, Brazil.

Authors:  Rodrigo Pessôa; Jaqueline Tomoko Watanabe; Paula Calabria; Alvina Clara Felix; Paula Loureiro; Ester C Sabino; Michael P Busch; Sabri S Sanabani
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

6.  Characterization of HIV-1 Near Full-Length Proviral Genome Quasispecies from Patients with Undetectable Viral Load Undergoing First-Line HAART Therapy.

Authors:  Brunna M Alves; Juliana D Siqueira; Marianne M Garrido; Ornella M Botelho; Isabel M Prellwitz; Sayonara R Ribeiro; Esmeralda A Soares; Marcelo A Soares
Journal:  Viruses       Date:  2017-12-19       Impact factor: 5.048

7.  Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.

Authors:  Sikhulile Moyo; Simani Gaseitsiwe; Melissa Zahralban-Steele; Dorcas Maruapula; Tapiwa Nkhisang; Baitshepi Mokaleng; Terence Mohammed; Tsotlhe R Ditlhako; Ontlametse T Bareng; Thatayaone P Mokgethi; Erik van Widenfelt; Molly Pretorius-Holme; Madisa O Mine; Elliot Raizes; Etienne Kadima Yankinda; Kathleen E Wirth; Tendani Gaolathe; Joseph M Makhema; Shahin Lockman; Max Essex; Vlad Novitsky
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

8.  HIV-1 diversity, drug-resistant mutations, and viral evolution among high-risk individuals in phase II HIV vaccine trial sites in southern China.

Authors:  Haiyan Qi; Ke Zhao; Fei Xu; Xuzhao Zhang; Zhiyong Zhang; Li Yang; Chunling Li; Xu Liang; Weigui Guo; Shihai Chen; Zhihao Liu; Wenyan Zhang; Xiao-Fang Yu
Journal:  PLoS One       Date:  2013-07-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.